Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The Company applys purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Its portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.
Company profile
Ticker
TFX
Exchange
Website
CEO
Liam Kelly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1902 Federal Road, LLC • Arrow Internacional de Chihuahua, S.A. de C.V. • Arrow Internacional de Mexico, S.A. de C.V. • Arrow International • Arrow Interventional, Inc. • Distribuidora Arrow, S.A. de C.V. • Essential Medical LLC • Hudson Respiratory Care Tecate, S. de R.L. de C.V. • ICOR AB • Inmed Manufacturing ...
IRS number
231147939
TFX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
24 Mar 23
PRE 14A
Preliminary proxy
10 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
8-K
Cost Associated with Exit or Disposal Activities
21 Nov 22
8-K
Entry into a Material Definitive Agreement
10 Nov 22
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Teleflex Reports Third Quarter Financial Results And Full Year Outlook
27 Oct 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
8-K
Teleflex Reports Second Quarter Financial Results And Full Year Outlook
28 Jul 22
Transcripts
TFX
Earnings call transcript
2022 Q4
23 Feb 23
TFX
Earnings call transcript
2022 Q3
27 Oct 22
TFX
Earnings call transcript
2022 Q2
28 Jul 22
TFX
Earnings call transcript
2022 Q1
28 Apr 22
TFX
Earnings call transcript
2021 Q4
24 Feb 22
TFX
Earnings call transcript
2021 Q3
28 Oct 21
TFX
Earnings call transcript
2021 Q2
29 Jul 21
TFX
Earnings call transcript
2021 Q1
2 May 21
TFX
Earnings call transcript
2020 Q4
28 Feb 21
TFX
Earnings call transcript
2020 Q3
2 Nov 20
Latest ownership filings
4
James Winters
28 Feb 23
4
Jay White
28 Feb 23
4
THOMAS E POWELL
28 Feb 23
4
Daniel V. Logue
28 Feb 23
4
Liam Kelly
28 Feb 23
4
Cameron P Hicks
28 Feb 23
4
John Deren
28 Feb 23
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Feb 23
SC 13G
MORGAN STANLEY
10 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 292.03 mm | 292.03 mm | 292.03 mm | 292.03 mm | 292.03 mm | 292.03 mm |
| Cash burn (monthly) | 35.08 mm | 12.75 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 105.85 mm | 38.49 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 186.18 mm | 253.54 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 5.3 | 19.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
96.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 471 |
| Opened positions | 79 |
| Closed positions | 61 |
| Increased positions | 167 |
| Reduced positions | 161 |
| 13F shares | Current |
|---|---|
| Total value | 11.17 tn |
| Total shares | 45.11 mm |
| Total puts | 82.50 k |
| Total calls | 145.50 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| T. Rowe Price Investment Management | 8.63 mm | $2.16 tn |
| Vanguard | 5.42 mm | $1.35 tn |
| BLK Blackrock | 3.97 mm | $990.92 bn |
| Wellington Management | 3.09 mm | $772.04 bn |
| MS Morgan Stanley | 2.69 mm | $671.80 bn |
| STT State Street | 2.28 mm | $570.25 bn |
| JHG Janus Henderson | 2.14 mm | $535.21 bn |
| T. Rowe Price | 1.22 mm | $305.23 bn |
| Geode Capital Management | 948.65 k | $237.00 bn |
| Allspring Global Investments | 803.40 k | $200.55 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Feb 23 | John Deren | Common Stock | Grant | Acquire A | No | No | 0 | 414 | 0.00 | 1,595 |
| 28 Feb 23 | John Deren | Stock Option / Common Stock | Grant | Acquire A | No | No | 238.23 | 2,886 | 687.53 k | 2,886 |
| 28 Feb 23 | Cameron P Hicks | Common Stock | Grant | Acquire A | No | No | 0 | 906 | 0.00 | 9,045.49 |
| 28 Feb 23 | Cameron P Hicks | Stock Option / Common Stock | Grant | Acquire A | No | No | 238.23 | 6,314 | 1.50 mm | 6,314 |
| 28 Feb 23 | Liam Kelly | Common Stock | Grant | Acquire A | No | No | 0 | 5,050 | 0.00 | 24,237.992 |
| 28 Feb 23 | Liam Kelly | Stock Option / Common Stock | Grant | Acquire A | No | No | 238.23 | 46,904 | 11.17 mm | 46,904 |
| 28 Feb 23 | Daniel V. Logue | Common Stock | Grant | Acquire A | No | No | 0 | 1,139 | 0.00 | 10,590.888 |
| 28 Feb 23 | Daniel V. Logue | Stock Option / Common Stock | Grant | Acquire A | No | No | 238.23 | 7,938 | 1.89 mm | 7,938 |
| 28 Feb 23 | Thomas E Powell | Common Stock | Grant | Acquire A | No | No | 0 | 2,357 | 0.00 | 14,384 |
| 28 Feb 23 | Thomas E Powell | Stock Option / Common Stock | Grant | Acquire A | No | No | 238.23 | 16,416 | 3.91 mm | 16,416 |
News
JMP Securities Reiterates Market Outperform on Teleflex, Maintains $330 Price Target
30 Mar 23
7 Analysts Have This to Say About Teleflex
27 Feb 23
Teleflex: Dividend Insights
27 Feb 23
Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $250
27 Feb 23
Looking Into Teleflex's Return On Invested Capital
24 Feb 23
Press releases
Teleflex Selects GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS® Stapler
29 Mar 23
UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH
13 Mar 23
Teleflex to Present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum: Virtual
7 Mar 23
Teleflex Announces Quarterly Dividend
23 Feb 23
Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23